Panitumumab
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Panitumumab (ncit:C1857)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | Wild type HRAS, Wild type KRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab | |
| FDA (1) | Wild type HRAS, Wild type KRAS | Colorectal Adenocarcinoma | Panitumumab | |
| EMA (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Oxaliplatin, Panitumumab | |
| EMA (2) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Fluorouracil, Irinotecan, Panitumumab | |
| EMA (1) HSE (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Panitumumab |